- Home
- IAS vs ADPT Comparison
IAS vs ADPT Comparison
Compare IAS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- ADPT
- Stock Information
- Founded
- IAS 2009
- ADPT 2009
- Country
- IAS United States
- ADPT United States
- Employees
- IAS N/A
- ADPT N/A
- Industry
- IAS Computer Software: Programming Data Processing
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IAS Technology
- ADPT Health Care
- Exchange
- IAS Nasdaq
- ADPT Nasdaq
- Market Cap
- IAS 1.3B
- ADPT 1.4B
- IPO Year
- IAS 2021
- ADPT 2019
- Fundamental
- Price
- IAS $8.30
- ADPT $11.55
- Analyst Decision
- IAS Buy
- ADPT Strong Buy
- Analyst Count
- IAS 11
- ADPT 7
- Target Price
- IAS $13.55
- ADPT $10.57
- AVG Volume (30 Days)
- IAS 956.2K
- ADPT 2.1M
- Earning Date
- IAS 07-31-2025
- ADPT 07-31-2025
- Dividend Yield
- IAS N/A
- ADPT N/A
- EPS Growth
- IAS 2607.38
- ADPT N/A
- EPS
- IAS 0.29
- ADPT N/A
- Revenue
- IAS $549,637,000.00
- ADPT $189,527,000.00
- Revenue This Year
- IAS $13.39
- ADPT $24.46
- Revenue Next Year
- IAS $11.41
- ADPT $20.25
- P/E Ratio
- IAS $28.03
- ADPT N/A
- Revenue Growth
- IAS 13.84
- ADPT 8.61
- 52 Week Low
- IAS $6.26
- ADPT $3.30
- 52 Week High
- IAS $13.62
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- IAS 51.72
- ADPT 79.12
- Support Level
- IAS $7.72
- ADPT $10.20
- Resistance Level
- IAS $8.25
- ADPT $10.85
- Average True Range (ATR)
- IAS 0.23
- ADPT 0.57
- MACD
- IAS -0.04
- ADPT 0.13
- Stochastic Oscillator
- IAS 50.34
- ADPT 89.33
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).